Cargando...

Glucagon-like Peptide-1 Receptor Agonists versus Sodium-Glucose Cotransporter Inhibitors for Treatment of T2DM

CONTEXT: Cardiovascular outcome trials (CVOT) of glucagon-like peptide-1 receptor agonists (GLP-1 RA) and sodium-glucose cotransporter 2 inhibitors (SGLT2i) demonstrated reduction of major adverse cardiovascular events (MACE), cardiovascular deaths (CVD), and renal outcomes. OBJECTIVE: Assist in the...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:J Endocr Soc
Autores principales: McKee, Alexis, Al-Khazaali, Ali, Albert, Stewart G
Formato: Artigo
Lenguaje:Inglês
Publicado: Oxford University Press 2020
Materias:
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC7182131/
https://ncbi.nlm.nih.gov/pubmed/32342023
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1210/jendso/bvaa037
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!